Interferon-γ response to pp65 stimulation before and after allogeneic bone marrow transplantation
. | . | . | ELISPOT IFN-γ spots/106 PBMCs . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Pt/dosage* . | Recipient CMV status prior to bone marrow transplantation . | Donor CMV status . | Before study . | After 3 injections . | After 6 injections . | 6 months after first immunization . | |||
| 1/1 | Negative | Negative | EDP | EDP | EDP | EDP | |||
| 2/1 | Negative | Positive | NE | NE | NE | NE | |||
| 3/1 | Negative | Negative | 0 | 0 | 0 | 0 | |||
| 4/1 | Negative | Positive | 322 | 392 | NE | 207 | |||
| 5/2 | Positive | Positive | 107 | 93 | 74 | 0 | |||
| 6/2 | Negative | Positive | 0 | 0 | 0 | 0 | |||
| 8/3 | Positive | Negative | 0 | 0 | 0 | 0 | |||
| 9/3 | Negative | Negative | 0 | 1 | 3 | 3 | |||
| 10/3 | Positive | Positive | 1247 | 1288 | 690 | 726 | |||
. | . | . | ELISPOT IFN-γ spots/106 PBMCs . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Pt/dosage* . | Recipient CMV status prior to bone marrow transplantation . | Donor CMV status . | Before study . | After 3 injections . | After 6 injections . | 6 months after first immunization . | |||
| 1/1 | Negative | Negative | EDP | EDP | EDP | EDP | |||
| 2/1 | Negative | Positive | NE | NE | NE | NE | |||
| 3/1 | Negative | Negative | 0 | 0 | 0 | 0 | |||
| 4/1 | Negative | Positive | 322 | 392 | NE | 207 | |||
| 5/2 | Positive | Positive | 107 | 93 | 74 | 0 | |||
| 6/2 | Negative | Positive | 0 | 0 | 0 | 0 | |||
| 8/3 | Positive | Negative | 0 | 0 | 0 | 0 | |||
| 9/3 | Negative | Negative | 0 | 1 | 3 | 3 | |||
| 10/3 | Positive | Positive | 1247 | 1288 | 690 | 726 | |||
Differences in IFN-γ secretion upon stimulation with pp65 were not statistically significant (P > .26) whether PBMCs were collected before or after immunization. Patient 7 (dose level 2) did not undergo transplantation.
PBMCs indicate peripheral blood mononuclear cells; EDP, early disease progression; and NE, not enough PBMCs available.
The dose-escalation schedule began at 2 × 105 CD40L-secreting skin fibroblasts per injection (dose level 1), increasing in log increments to 2 × 107 (dose level 3). IL-2-secreting skin fibroblasts and recipient-derived blasts were administered at a fixed dosage throughout the study (2 × 107 per injection)